Posted by Michael Wonder on 10 Oct 2024
Volixibat granted breakthrough therapy designation for cholestatic pruritus in primary biliary cholangitis
10 October 2024 - Designation based on positive interim analysis of Phase 2b VANTAGE study.
Mirum Pharmaceuticals today announced that the US FDA has granted breakthrough therapy designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis.
